The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
is the total length of the capillary. Since only charged ions are affected by the electric field, neutral analytes are poorly separated by capillary electrophoresis. The velocity of migration of an analyte in capillary electrophoresis will also depend upon the rate of electroosmotic flow (EOF) of the buffer solution. In a typical system, the electroosmotic flow is directed toward the negatively charged cathode so that the buffer flows through the capillary from the source vial to the destination vial. Separated by differing electrophoretic mobilities, analytes migrate toward the electrode of opposite charge. As a result, negatively charged analytes are attracted to the positively charged anode, counter to the EOF, while positively charged analytes are attracted to the cathode, in agreement with the EOF as depicted in figure 3.
CAKKRNWCGK NEDCCCPMKC IYAWYNQQGS CQTTITGLFK KC Cysteine bridges exist between Cys1 and Cys15, Cys8 and Cys20, Cys14 and Cys31, and Cys16 and Cys42. The structure consists of a small triple-stranded beta-sheet stabilized by a disulfide knot, followed by a C-terminal extension comprising three classic or inverse y-turns. The disulfide knot is a ring consisting of two disulfide bonds (1-15 and 8-20) and the connecting backbone, through which a third disulfide bond (14–31) passes. The β-sheet, defined on the basis of inter-sheet hydrogen bonds, consists of residues 6-8 (strand I), 19-21 (strand II) and 29-32 (strand III), with a topology of +2x, —1. The two hydrogen bonds (one amide of which has a slowly exchanging amide proton) between strands I and III are distorted (NH to CO distance between 2.5 and 3.0 A). There are four hydrogen bonds between strands II and III (all of which have corresponding slowly exchanging amide protons), three being present in most of the structures and one in half of the structures. The structure contains a number of chain reversals. The first is not well defined and is either a type II β-turn (Lys3-Asn6) or a y-turn centered on Arg5. Chain reversal II is a y turn centered on Gly9. Chain reversal III is not well defined, being either a type I β-turn (Asnn-Cys14) or an inverse y-turn centered on Asn11. Chain reversal IV (Cys15-Met18) is not stabilized by a hydrogen bond but has a cis peptide bond between Cys16 and Pro17 and resembles a type Via turn.
{\displaystyle {\begin{aligned}\nabla \varphi &=\left({\frac {\partial \varphi }{\partial x}},\,{\frac {\partial \varphi }{\partial y}}\right)^{\mathsf {T}},\\[5pt]\nabla \times \varphi &=\left({\frac {\partial \varphi }{\partial y}},\,-{\frac {\partial \varphi }{\partial x}}\right)^{\mathsf {T}}.\end{aligned}}}
Sources: en.wikipedia.org
== Uses == Fluorene is a precursor to other fluorene compounds; the parent species has few applications. Fluorene-9-carboxylic acid is a precursor to pharmaceuticals. Oxidation of fluorene gives fluorenone, which is nitrated to give commercially useful derivatives. 9-Fluorenylmethyl chloroformate (Fmoc chloride) is used to introduce the 9-fluorenylmethyl carbamate (Fmoc) protecting group on amines in peptide synthesis. Polyfluorene polymers (where carbon 7 of one unit is linked to carbon 2 of the next one, displacing two hydrogens) are electrically conductive and electroluminescent, and have been much investigated as a luminophore in organic light-emitting diodes. Fluorene is used to make 9-benzylfluorene [1572-46-9]. The importance of this is that it is used in the synthesis of UCL 1608 [371172-30-4], a medicine discovered by C. Robin Ganellin & Co.
=== Organic chemistry === In organic chemistry, menthol is used as a chiral auxiliary in asymmetric synthesis. For example, sulfinate esters made from sulfenyl chlorides and menthol can be used to make enantiomerically pure sulfoxides by reaction with organolithium reagents or Grignard reagents. Menthol reacts with chiral carboxylic acids to give diastereomic menthyl esters, which are useful for chiral resolution.
=== Paleomagnetic dating === A sequence of paleomagnetic poles (usually called virtual geomagnetic poles), which are already well defined in age, constitutes an apparent polar wander path (APWP). Such a path is constructed for a large continental block. APWPs for different continents can be used as a reference for newly obtained poles for the rocks with unknown age. For paleomagnetic dating, it is suggested to use the APWP in order to date a pole obtained from rocks or sediments of unknown age by linking the paleopole to the nearest point on the APWP. Two methods of paleomagnetic dating have been suggested: (1) the angular method and (2) the rotation method. The first method is used for paleomagnetic dating of rocks inside of the same continental block. The second method is used for the folded areas where tectonic rotations are possible.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.